AbbVie Inc. $ABBV Shares Acquired by Guerra Advisors Inc

Guerra Advisors Inc lifted its stake in shares of AbbVie Inc. (NYSE:ABBV) by 45.0% during the 3rd quarter, Holdings Channel reports. The fund owned 15,071 shares of the company’s stock after buying an additional 4,678 shares during the quarter. AbbVie comprises 1.3% of Guerra Advisors Inc’s portfolio, making the stock its 26th largest holding. Guerra Advisors Inc’s holdings in AbbVie were worth $3,490,000 at the end of the most recent quarter.

Other hedge funds have also recently modified their holdings of the company. Evolution Wealth Management Inc. purchased a new stake in AbbVie in the 2nd quarter valued at about $26,000. Spurstone Advisory Services LLC acquired a new stake in shares of AbbVie during the second quarter valued at about $28,000. Financial Gravity Companies Inc. purchased a new stake in shares of AbbVie in the 2nd quarter valued at approximately $36,000. Bear Mountain Capital Inc. lifted its holdings in shares of AbbVie by 480.6% in the 2nd quarter. Bear Mountain Capital Inc. now owns 209 shares of the company’s stock worth $40,000 after acquiring an additional 173 shares during the last quarter. Finally, Delos Wealth Advisors LLC acquired a new stake in AbbVie in the 2nd quarter valued at approximately $39,000. Hedge funds and other institutional investors own 70.23% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts have commented on ABBV shares. Morgan Stanley upped their price target on AbbVie from $261.00 to $269.00 and gave the stock an “overweight” rating in a research note on Friday, December 12th. UBS Group reissued a “neutral” rating on shares of AbbVie in a research note on Tuesday, January 13th. Hsbc Global Res upgraded AbbVie from a “hold” rating to a “strong-buy” rating in a report on Wednesday, December 10th. JPMorgan Chase & Co. lifted their target price on AbbVie from $250.00 to $260.00 and gave the company an “overweight” rating in a research report on Monday, November 3rd. Finally, Cantor Fitzgerald set a $250.00 price target on shares of AbbVie and gave the stock an “overweight” rating in a research note on Thursday, October 9th. Two research analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating and eight have issued a Hold rating to the company. According to data from MarketBeat, AbbVie presently has a consensus rating of “Moderate Buy” and an average target price of $249.37.

AbbVie Price Performance

ABBV stock opened at $223.02 on Monday. The business’s 50-day moving average is $224.40 and its two-hundred day moving average is $218.66. The firm has a market capitalization of $394.15 billion, a P/E ratio of 168.95, a P/E/G ratio of 0.92 and a beta of 0.36. AbbVie Inc. has a 1 year low of $164.39 and a 1 year high of $244.81.

AbbVie (NYSE:ABBV) last released its earnings results on Friday, October 31st. The company reported $1.86 earnings per share for the quarter, topping analysts’ consensus estimates of $1.77 by $0.09. AbbVie had a net margin of 4.00% and a return on equity of 3,216.47%. The firm had revenue of $15.78 billion for the quarter, compared to analyst estimates of $15.58 billion. During the same period in the prior year, the firm earned $3.00 earnings per share. The business’s quarterly revenue was up 9.1% compared to the same quarter last year. On average, analysts expect that AbbVie Inc. will post 12.31 EPS for the current year.

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.